Global Blood Therapeutics
Small molecule therapeutic that stabilizes red blood cells in sickle cell disease
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2011
- Latest Form D
- $48M, Jan 2015
- Total capital
- $48.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $48M
- 1 Form D · last Jan 2015
- 142 months since last filing
- Federal contracts
- $219K
- 5 awards · Justice
- Rank in Biotech#287 of 4373
- Granted patents
- 16
- 24 pending · first 2022
- Rank in peer group#30 of 1449
Capital timeline
Latest events
- Federal contractJustice · Oxbryta Medication$94K
- Federal contractJustice · Oxbryta Medication$63K
- Federal contractJustice · Oxbryta Medication 2 Month Supply$21K
- Federal contractJustice · Voxelotor (oxbryta) 500MG (90CT - 30 Day Supply) Inmate Evans, Curtis 28970-009 Sickle Cell Med Or - 11849 Onboarding Name$42K
- Private capital raisedForm D · SEC · 1st filing$48M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#30 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Charles W. Homcy, M.D.DirectorNamed in SEC Form D filings
- John W. SchembriExecutive OfficerNamed in SEC Form D filings
- Kevin W. StarrDirectorNamed in SEC Form D filings
- Ted W. LoveExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 16 granted of 40- PendingMethods Of Administering VoxelotorUSPTOApplication 18707329
- GrantedModulators Of HemoglobinUSPTOUS 12,649,719
- PendingModulators Of HemoglobinUSPTOApplication 19421948
Show all 40 patent records
- Methods Of Administering VoxelotorJun 11, 2026 · Application 18707329Pending
- Modulators Of HemoglobinJun 9, 2026 · US 12,649,719Granted
- Modulators Of HemoglobinApr 16, 2026 · Application 19421948Pending
- Thieno Pyrimidines As Ferroportin InhibitorsFeb 24, 2026 · US 12,559,502Granted
- Solid Forms Of A Modulator Of HemoglobinNov 18, 2025 · US 12,473,277Granted
- Cycloalkyl Pyrimidines As Ferroportin InhibitorsApr 3, 2025 · Application 18954838Pending
- Methods Of Administering A Modulator Of HemoglobinFeb 6, 2025 · Application 18717181Pending
- Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehydeJan 30, 2025 · Application 18912432Pending
- Cycloalkyl Pyrimidines As Ferroportin InhibitorsJan 21, 2025 · US 12,202,817Granted
- Methods Of Making A Modulator Of HemoglobinJan 2, 2025 · Application 18585711Pending
- Tablets Comprising 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEDec 26, 2024 · Application 18830475Pending
- Lactam Pyrrolidine-pyrazoles As Pyruvate Kinase ActivatorsDec 12, 2024 · Application 18698516Pending
- Dosing Regimens For 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEApr 2, 2024 · US 11,944,612Granted
- Methods Of Making A Modulator Of HemoglobinMar 26, 2024 · US 11,939,323Granted
- Solid Forms Of A Modulator Of HemoglobinDec 26, 2023 · US 11,851,424Granted
- Compounds And Uses Thereof For The Modulation Of HemoglobinOct 12, 2023 · Application 17981140Pending
- Urea Derivatives As Pyruvate Kinase ActivatorsSep 7, 2023 · Application 18019379Pending
- Cycloalkyl Pyrimidines As Ferroportin InhibitorsSep 5, 2023 · US 11,746,100Granted
- Histone Methyltransferase InhibitorsAug 1, 2023 · US 11,713,299Granted
- Methods Of Use For Pyrimidines As Ferroportin InhibitorsJul 20, 2023 · Application 17997273Pending
- Process For Synthesizing 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDEJul 13, 2023 · Application 17895619Pending
- Process For Preparation Of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEJun 8, 2023 · Application 18102440Pending
- Tricyclic Compounds As Histone Methyltransferase InhibitorsMay 30, 2023 · US 11,661,410Granted
- Pyrrolidine-pyrazoles As Pyruvate Kinase ActivatorsMay 25, 2023 · Application 17916530Pending
- Modulators Of HemoglobinMay 25, 2023 · Application 17991448Pending
- Pyrrolidine-pyrazoles As Pyruvate Kinase ActivatorsMay 18, 2023 · Application 18155304Pending
- Tricyclic Compounds As Histone Methyltransferase InhibitorsFeb 21, 2023 · US 11,584,734Granted
- SUBSTITUTED 2,6-DIHYDROPYRROLO[3,4-c]PYRAZOLES AS PYRUVATE KINASE ACTIVATORSJan 31, 2023 · US 11,566,030Granted
- Methods Of Administering VoxelotorJan 19, 2023 · Application 17777909Pending
- Modulators Of HemoglobinJan 10, 2023 · US 11,548,880Granted
- Compounds And Uses Thereof For The Modulation Of HemoglobinDec 22, 2022 · Application 17887062Pending
- Compounds And Uses Thereof For The Modulation Of HemoglobinDec 20, 2022 · US 11,530,191Granted
- Crystalline Polymorphs Of The Free Base Of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEDec 15, 2022 · Application 17885238Pending
- Process For Preparation Of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEOct 13, 2022 · Application 17843283Pending
- Crystalline Polymorphs Of The Free Base Of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDESep 27, 2022 · US 11,452,720Granted
- Process For Preparation Of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEMay 12, 2022 · Application 17520453Pending
- Process For Synthesizing 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDEMay 5, 2022 · Application 17571762Pending
- Compounds And Uses Thereof For The Modulation Of HemoglobinApr 21, 2022 · Application 17567605Pending
- Dosing Regimens For 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEApr 14, 2022 · Application 17559156Pending
- Ferroportin Inhibitors And Methods Of UseMar 29, 2022 · US 11,286,243Granted
Related companies, and why
- HERA HEALTH SOLUTIONS INCSimilar federal contract value in Biotech · $250K in contracts
- ERIVAN BIO, LLCSimilar federal contract value in Biotech · $250K in contracts
- LaCell LLCSimilar federal contract value in Biotech · $235K in contracts
- THERMOGENESIS CORP.Similar federal contract value in Biotech · $218K in contracts
- ZoneOne PharmaSimilar federal contract value in Biotech · $216K in contracts
- Edesa Biotech, Inc.Similar federal contract value in Biotech · $214K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .